Valeant Pharmaceuticals is expanding its Canadian manufacturing and export capacity, investing $27.5 million in its Steinbach, Manitoba and Laval, Quebec manufacturing facilities.   The company will invest $15 million in its Steinbach facility, including $7 million in upgrades to product manufacturing technology and $8 million for the transfer of North American production of Xifaxan and Apriso. These drugs are used to treat hepatic encephalopathy and irritable bowel syndrome, and ulcerative co...